Last reviewed · How we verify

NCT07504250: HAM-DCR

Hyaluronic Acid vs Mitomycin-C in External Dacryocystorhinostomy

Not yet recruiting Phase 4 Last updated 31 March 2026
What this trial tests

Phase 4 trial testing Hyaluronic Acid (HA) in Dacryocystitis in 36 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
30 October 2027
31 December 2027

Quick facts

Lead sponsorAll India Institute of Medical Sciences, Bhubaneswar
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment36
Start date1 April 2026
Primary completion30 October 2027
Estimated completion31 December 2027

Drugs / interventions tested

Conditions studied

Sponsor

All India Institute of Medical Sciences, Bhubaneswar

Who can join

Adults 18 to 65, any sex, with Dacryocystitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RCT to compare the surgical success in patients undergoing external dacryocystorhinostomy with intraoperative Mitomycin-C (0.4 mg/ml) Vs Hyaluronic acid 1% (1ml) as adjuvant, To compare the complication rates and wound healing patterns in each group, To Compare change in tear MMP-9 levels from preoperative (within 1 week before surgery) to postoperative (6 weeks after surgery) , To compare the comfort levels of patients in each group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hyaluronic Acid (HA)

Trials testing the same drug.

Other recruiting trials for Dacryocystitis

Currently open trials in the same condition.

Other All India Institute of Medical Sciences, Bhubaneswar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07504250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing